519 672 2121
Close mobile menu
Published on: 11 Oct 2023 By

Proposed changes to the Competition Act could affect your business

On September 21, 2023, Bill C-56—also known as the Affordable Housing and Groceries Act—received its first reading in the House of Commons. The Bill proposes several changes to Canada’s Competition Act. One such change is a significant expansion of the government’s power to conduct inquiries…

View the post titled Proposed changes to the Competition Act could affect your business
Published on: 2 Oct 2023 By

Power of attorney issues: Compensation for powers of attorney for property

If you have been named as an attorney for property1 pursuant to a continuing power of attorney for property, you may be wondering whether or not you are entitled to receive compensation for acting in this capacity and, if so, how that compensation is calculated. This is a fair question to as…

View the post titled Power of attorney issues: Compensation for powers of attorney for property
Published on: 28 Sep 2023 By

Notice periods for personal injury claims in Ontario

When you are injured, your immediate focus should be on your health and recovery. However, when you have sustained an injury due to someone else’s negligence or wrongdoing in Ontario, there is often a requirement to provide notice of your injury to the negligent party within a certain period…

View the post titled Notice periods for personal injury claims in Ontario
Published on: 27 Sep 2023 By

What is the Income Replacement Benefit under the Statutory Accident Benefits Schedule?

A person’s contract with their own auto insurance company includes the potential payment of Income Replacement Benefits. This benefit is mandatory to all Ontario automobile insurance policies and it is defined under section 4 of the Statutory Accident Benefits Schedule (SABS). The Income Rep…

View the post titled What is the Income Replacement Benefit under the Statutory Accident Benefits Schedule?
Published on: 27 Sep 2023 By

Navigating the complex world of Letters of Intent: A buy-side guide

In the rapidly paced, high-stakes game of mergers and acquisitions (M&As), the first move is not dissimilar to a game of chess; a good opening will set the pace for the rest of the game. In M&A deals, the first move must be similarly strategic, resembling an orchestrated dance that…

View the post titled Navigating the complex world of Letters of Intent: A buy-side guide
Published on: 21 Sep 2023 By
Video Icon

Understanding privacy impact assessments (PIAs) and their importance for your business

In the ever-evolving data privacy landscape, businesses must stay ahead of the curve to protect themselves and their customers. One crucial tool that can help you navigate this complex terrain is a privacy impact assessment, or PIA. What is a privacy impact assessment (PIA)? Privacy impact a…

View the post titled Understanding privacy impact assessments (PIAs) and their importance for your business
Published on: 12 Sep 2023 By

What qualifies as an “accident” under the Statutory Accident Benefits Schedule?

Statutory Accident Benefits (SABS) provides financial support to individuals involved in accidents that are covered under a car insurance policy. It is essential to have a clear understanding of what constitutes an accident in order to determine one’s eligibility for these benefits. What exa…

View the post titled What qualifies as an “accident” under the Statutory Accident Benefits Schedule?
Published on: 23 Aug 2023 By

Ozempic for weight loss? Know the risks of off-label prescriptions

Ozempic (semaglutide) is a prescription drug approved to treat type 2 diabetes that has become one of the most in-demand medications in North America in recent years. Demand for Ozempic, which is manufactured by Novo Nordisk, has driven shortages in the United States. Health Canada observed …

View the post titled Ozempic for weight loss? Know the risks of off-label prescriptions
Published on: 9 Aug 2023 By

Bladder drug Elmiron – linked to vision loss, macular degeneration – still among top non-patented drugs in Canada per 2023 report

Elmiron, a medication prescribed for bladder issues that has been linked to a unique form of macular degeneration causing vision loss, continues to rank among the top publicly funded non-patented drugs in Canada, according to a government report on public drug plan expenditures published ear…

View the post titled Bladder drug Elmiron – linked to vision loss, macular degeneration – still among top non-patented drugs in Canada per 2023 report